Screener
Geron GERN Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Geron in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Geron’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:41 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886744-26-000037
| Line item | THREE MONTHS ENDEDJUNE 30, 2026 | THREE MONTHS ENDEDJUNE 30, 2025 | SIX MONTHS ENDEDJUNE 30, 2026 | SIX MONTHS ENDEDJUNE 30, 2025 |
|---|---|---|---|---|
| Total costs and operating expenses | 69,976 | 61,490 | 121,655 | 117,797 |
| Loss from operations | (12,496) | (12,454) | (12,338) | (29,158) |
| Interest income | 2,971 | 4,656 | 6,392 | 9,808 |
| Interest expense | (7,146) | (8,516) | (14,293) | (16,716) |
| Other income (expense), net | (9) | (61) | (83) | (144) |
| Net loss | $(16,680) | $(16,375) | $(20,322) | $(36,210) |
| Basic and diluted net loss per share | $(0.02) | $(0.02) | $(0.03) | $(0.05) |
| Weighted-average shares used in calculating basic and diluted net loss per share | 670,696 | 666,170 | 670,039 | 666,039 |
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)
FAQ
- What is Geron's business segments — net loss?
- Geron (GERN) reported business segments — net loss of -$16.7M in Q2 2026.
- How has Geron's business segments — net loss changed year-over-year?
- Geron's business segments — net loss decreased by 1.8% year-over-year, from -$16.4M to -$16.7M.
- What does business segments — net loss mean?
- Represents the final bottom-line result for the segment after accounting for all revenues, operating expenses, restructuring charges, and non-operating items. A persistent net loss is typical for clinical-stage biopharmaceutical segments heavily invested in long-term research and development.
Ask your AI about Geron's business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude